Qinghong Zhou
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Qinghong Zhou as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:17 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07349329 · A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · not yet recruiting · Axial Spondyloarthritis, Non-Radiographic · study director
- Ph2NCT06270225 · A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · unknown · Gout Arthritis · study director
- Ph2NCT06222671 · A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · recruiting · Axial Spondyloarthritis · study director
- Ph3NCT06169891 · A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute GoutSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · unknown · Acute Gout · study director
- Ph1NCT05966701 · The MAD Study of SSGJ-613 in Healthy SubjectsSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · unknown · Arthritis, Gouty · study director
- Ph2NCT05865496 · A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal PolypsSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · unknown · Sinusitis, Nasal Polyps, Polyps · study director
- Ph1/Ph2NCT05588908 · A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute GoutSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · unknown · Acute Gout · study director
- Ph1NCT05584306 · A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic AsthmaSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · unknown · Asthma · study director
- Ph3NCT05536726 · A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque PsoriasisSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · completed · Psoriasis · study director
- Ph2NCT05528679 · A Phase II Study of 610 in Participants With Severe Eosinophilic AsthmaSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · unknown · Asthma · study director
- Ph1NCT03641794 · Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy VolunteersJiangxi Qingfeng Pharmaceutical Co. Ltd. · unknown · Advanced Solid Tumors · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:17 UTC. The ranking covers the 200 most relevant of 577 PubMed records, and a shared surname and initials can bring in a namesake. All 577 on PubMed
- 993 citationsRCR 29.3
- Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.Lancet · 2017777 citationsRCR 35.3
- High-frequency oscillation in early acute respiratory distress syndrome.N Engl J Med · 2013586 citationsRCR 21.8
- 463 citationsRCR 14.6
- Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula.ISME J · 2015346 citationsRCR 13.2
- Interferon-α2b Treatment for COVID-19.Front Immunol · 2020301 citationsRCR 13.3
- Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.Gastroenterology · 2020279 citationsRCR 13.8
- 233 citationsRCR 12.9
- Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.Cancer Cell · 2021218 citationsRCR 10.3
- Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.Lancet Oncol · 2023200 citationsRCR 17.0